Crossmark

Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial

Crossref DOI link: https://doi.org/10.1007/s10157-024-02589-1

Published Online: 2025-01-02

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Higashihara, Eiji https://orcid.org/0000-0002-6663-9910
Matsukawa, Miyuki

Jiang, Huan
License Information

Text and Data Mining valid from 2025-01-02

Version of Record valid from 2025-01-02
More Information

Article History

Received: 30 July 2024

Accepted: 3 November 2024

First Online: 2 January 2025

Declarations

:

: EH has no conflict of interest to declare. MM is an employee of Otsuka Pharmaceutical Co., Ltd., Japan. HJ is an employee of Otsuka Pharmaceutical Development & Commercialization, USA.

Document is current

Any future updates will be listed below